“First generation TAVI devices provide significant clinical benefit, but there are opportunities for improvement,” explained lead author Ian Meredith, Director of MonashHeart, Southern Health and Professor of Medicine, Monash University, Melbourne, Australia. He suggested that these include controlled deployment, simple, precise and atraumatic aortic/ventricular repositioning, no or trivial paravalvular leakage and lower complication rate.
Commenting on the implications of the study findings, Stephan Windecker, Professor and Chief of Cardiology, Swiss Cardiovascular Center and Clinical Trials Unit Bern, Bern University Hospital, Switzerland, said, “An important factor is that this is a truly repositional device. And it is exciting that the rate of moderate to severe aortic regurgitation is so low.”
“Angiographic assessment of chest pain is flawed because it doesn’t assess the functional significance of coronary artery disease,” said the lead author of the study Nick Curzen, Professor of Interventional Cardiology, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine, University of Southampton, Southampton, UK.
Commenting on the implications of the study findings, Professor Stephan Windecker, Professor and Chief of Cardiology, Swiss Cardiovascular Center and Clinical Trials Unit Bern, Bern University Hospital, Switzerland, said, “The field of transcutaneous aortic valve implantation is expanding in indications from its well established use in aortic stenosis to other causes of aortic regurgitation. The larger annulus size in patients with aortic insufficiency without stenosis means we need facilitating techniques to use devices previously used in aortic stenosis. In this study it is encouraging to treat patients with aortic regurgitation for which we have not previously had suitable devices.”
“TAVI has become a treatment option for selected patients with symptomatic severe aortic stenosis. But current data are virtually all from North American or European centres,” Paul Chiam, senior consultant cardiologist at the National Heart Center, Singapore, told the conference. He explained that it is unknown whether the smaller average physique in Asian patients may affect outcomes after TAVI.
Commenting on the implications of the study findings, Chiam concluded, “Early experience suggests that TAVI appears feasible and safe in a physically smaller Asian population, with low stroke and mortality rates and without an increase in vascular complications.”
What is EuroPCR?EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) and the world-leading course in interventional medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore, London, Dubai and Cape Town.For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR & PCR, please contact: Anne-Sophie Lartigau at firstname.lastname@example.org
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved